Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2
- First Online:
- Cite this article as:
- Khochenkov, D.A., Solomko, E.S., Peretolchina, N.M. et al. Bull Exp Biol Med (2015) 160: 84. doi:10.1007/s10517-015-3104-5
- 70 Downloads
Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis.